A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: Tumor response and its correlation with clinical benefit response, and preliminary quality of life data

Scheele, Colinda L.G.J.

doi:10.3892/or_00000512

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical studies of AMT are only at their beginning, but tend to confirm the preclinical data. In a pilot study in women with advanced cervical cancer, AMT was well tolerated and improved the quality of life [39]. Interestingly, the presented patient complained about dizziness during AMT treatment.…”

Section: Discussionmentioning

confidence: 99%

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report

et al. 2011

View full text Add to dashboard Cite

IntroductionAuron Misheil Therapy was developed based on similarities between carcinogenesis and inflammation. Auron Misheil Therapy is a combination of natural and synthetic compounds, including anti-inflammatory drugs and insulin, expected to exhibit synergistic effects.Case presentationHere, we report the case of a 78-year-old Caucasian male patient who presented with multifocal hepatocellular carcinoma and chronic hepatitis C virus infection. Over a four-year period our patient was treated with radiofrequency ablation and transarterial chemoembolization. After these treatments there was tumor progression, with new hyperperfused lesions without evidence of extrahepatic tumor involvement. Our patient refused sorafenib therapy. Therefore, he received twice daily intramuscular injections of Auron Misheil Therapy on an outpatient basis for two months. Partial remission of the hepatic lesions was observed eight weeks after the start of treatment, and confirmed four weeks later. Unfortunately, at that time our patient refused therapy due to dizziness. During follow-up two target lesions remained stable, but one lesion increased in size. At the latest follow-up, one year later, there was still tumor control.ConclusionWhile the mechanisms underlying the antitumor effects of Auron Misheil Therapy are not fully understood, stable disease and remissions have been observed in different types of tumors, including hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The anticancer activity of AMT has also been observed in in vivo studies with human xenografts and in a clonogenic assay 1 . Preliminary clinical data indicate that AMT is safe, and that it may be clinically useful as an anticancer agent 2,3 …”

Section: Introductionmentioning

confidence: 99%

Effects of Auron‐Misheil‐Therapy in human in vitro skin models

Scheele¹,

Mappes²,

Dorn

et al. 2010

The Journal of Dermatology

View full text Add to dashboard Cite

Auron-Misheil-Therapy (AMT) is currently under development as an anticancer treatment. The aim of the present study was the identification of possible effects and properties of AMT with regard to human skin. The study consisted of three experimental phases. Phase 1 assessed the effects of AMT on the viability of 2-D evaluated and accredited cell cultures of three cell types of human skin, namely: keratinocytes, melanocytes and fibroblasts. Three separate assays were used in this phase. Phase 2 was designed to clarify the effects of AMT on cell viability to investigate the mode of action of AMT. Two possible modes of action were investigated: proliferation inhibition and apoptosis. There was one assay to assess proliferation, and two independent assays to assess apoptosis. The third phase assessed the effects of AMT on two different types of 3-D skin models, an ex vivo model and a de novo reconstituted model. In the phase 1 tests, reduction of cell viability by AMT was demonstrated in all three cell types. In phase 2, the cell proliferation assay showed decreased proliferation rates in the presence of AMT in three out of four cell populations. In phase 3, histochemical investigations with 3-D models indicated that AMT induces desquamation, most likely as the result of apoptosis of epidermal cells. The experiments generally showed that AMT does not harm human skin at concentrations up to 3%.

show abstract

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

Xue

2011

Chin. J. Integr. Med.

View full text Add to dashboard Cite

"Living with cancer" and symptom control are the features and advantages of integrative medicine in advanced non-small cell lung cancer (NSCLC) treatment. However, with the current concept of response evaluation criteria by the WHO and RECIST, it is difficult to exhibit the above characteristics. Clinical benefit (CB) is designed as an endpoint recently widely understood and accepted in oncology clinical trials. With the review of its definition and development, we suggest CB to be used as an endpoint in advanced NSCLC treatment with integrative medicine. CB should encompass two connotations: one is improved quality of life and symptom control and the other is disease control rate (DCR), including complete response (CR), partial response (PR), and stable disease (SD). We need to design randomized controlled trials (RCT) to investigate the interrelationship of CB rate and survival to provide high-grade evidence proving that advanced lung cancer patients could really benefit from integrative medicine treatment.

show abstract

A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: Tumor response and its correlation with clinical benefit response, and preliminary quality of life data

Cited by 3 publications

References 19 publications

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report

Clinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report

Effects of Auron‐Misheil‐Therapy in human in vitro skin models

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

Contact Info

Product

Resources

About